Oncotelic Therapeutics Inc

OTCPK:OTLC (USA)  
$ 0.04 -0.00002 (-0.06%) 11:08 PM EST
At Loss
P/B:
1.20
Market Cap:
$ 14.36M
Enterprise V:
$ 26.49M
Volume:
74.47K
Avg Vol (2M):
81.83K
Volume:
74.47K
At Loss
Avg Vol (2M):
81.83K

Business Description

Oncotelic Therapeutics Inc
NAICS : 325412 SIC : 2834
ISIN : US57667K1097
Description
Oncotelic Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing drugs for the treatment of orphan oncology indications, developing antisense and small molecule injectable drugs for the treatment of cancer with a focus on rare pediatric cancers, and addressing the current global pandemic. OT-101 is its lead immuno-oncology drug candidate. OT-101 also has activity against SARS-CoV-2. Its other products under pipeline are Artemisinin, CA4P, and Oxi4503. Currently, the company generates revenues from rendering services to other third-party customers for the development of certain drug products or in connection with certain out-licensing agreements.

Financial Strength

Name Current Vs Industry Vs History
Cash-To-Debt 0.02
Equity-to-Asset 0.42
Debt-to-Equity 0.99
Debt-to-EBITDA -1.13
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -2.9
Distress
Grey
Safe
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year EPS without NRI Growth Rate 47.7
3-Year FCF Growth Rate 57.1
3-Year Book Growth Rate -37.1

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 40.35
9-Day RSI 43.29
14-Day RSI 45.01
6-1 Month Momentum % 21.29
12-1 Month Momentum % -23.11

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 0.02
Quick Ratio 0.02
Cash Ratio 0.02
Days Sales Outstanding 102.2

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -67
Shareholder Yield % -14.68

Profitability Rank

Name Current Vs Industry Vs History
Operating Margin % -1291.43
Net Margin % -17794.29
FCF Margin % -1471.43
ROE % -71.42
ROA % -36.1
ROIC % -1.86
ROCE % -63.24
Years of Profitability over Past 10-Year 1

Financials (Next Earnings Date:2024-04-12 Est.)

OTLC's 30-Y Financials
Income Statement Breakdown
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with OTCPK:OTLC

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Oncotelic Therapeutics Inc Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 0.07
EPS (TTM) ($) -0.041
Beta -0.03
Volatility % 50.36
14-Day RSI 45.01
14-Day ATR ($) 0.004688
20-Day SMA ($) 0.03828
12-1 Month Momentum % -23.11
52-Week Range ($) 0.01 - 0.055
Shares Outstanding (Mil) 399.18

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Oncotelic Therapeutics Inc Filings

Filing Date Document Date Form
No Filing Data

Oncotelic Therapeutics Inc Stock Events

Financials Calendars
Event Date Price($)
No Event Data

Oncotelic Therapeutics Inc Frequently Asked Questions

What is Oncotelic Therapeutics Inc(OTLC)'s stock price today?
The current price of OTLC is $0.04. The 52 week high of OTLC is $0.06 and 52 week low is $0.01.
When is next earnings date of Oncotelic Therapeutics Inc(OTLC)?
The next earnings date of Oncotelic Therapeutics Inc(OTLC) is 2024-04-12 Est..
Does Oncotelic Therapeutics Inc(OTLC) pay dividends? If so, how much?
Oncotelic Therapeutics Inc(OTLC) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1